Skip to main content

Long-Term Low-Carb Diet Efficacious for Treating Dyslipidemia in T2D

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Aug 4, 2024.

via HealthDay

FRIDAY, Aug. 2, 2024 -- For individuals with type 2 diabetes, long-term low-carbohydrate diets (LCD) are efficacious for treatment of dyslipidemia but do not affect glycemic control, according to a review published online July 24 in the Journal of Diabetes Investigation.

Takahiro Ichikawa, from the Kyoto Prefectural University of Medicine in Japan, and colleagues conducted a systematic review to examine the association between long-term LCD and glycemic control in individuals with type 2 diabetes. Six studies met the inclusion criteria.

The researchers found no significant differences in changes in glycated hemoglobin (HbA1c) between long-term LCD and control diets. Furthermore, between long-term and control diets, there were no significant differences in the changes in weight loss, blood pressure, and low-density lipoprotein cholesterol. Compared with control diets, long-term LCD were associated with greater elevation in high-density lipoprotein cholesterol (standardized mean difference, 0.22) and a decrease in triglyceride levels (standardized mean difference, −0.19).

"Long-term LCD might be an important approach in the management of diabetic dyslipidemia in individuals with type 2 diabetes," the authors write. "However, in the present study, long-term LCD were not found to be more effective than control diets in the reduction of HbA1c levels."

Several authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Risk for Dementia, Ischemic Stroke, Mortality Lower With GLP-1 Receptor Agonists in T2D, Obesity

TUESDAY, July 22, 2025 -- For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke...

ENDO: Guidelines Developed for Pregnancy Care in Preexisting Diabetes

FRIDAY, July 18, 2025 -- In a joint clinical practice guideline issued by the Endocrine Society and European Society of Endocrinology, recommendations are presented for pregnancy...

ENDO: Older Age, Female Sex Tied to Greater Muscle Loss With Semaglutide

THURSDAY, July 17, 2025 -- Older age and female sex may be associated with greater muscle loss in adults with obesity prescribed semaglutide, and greater muscle loss is...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.